Add To Watchlist
Share URL
About The Company
Description
SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions.
Read More
Overview
Value
1
Growth
31
Health
45
Management
11
Analyst Opinion
69
Total
31
All Scores Out Of 100
Best Features
- Earnings growth has improved recently
- Has a low level of debt
- Has a history of share buybacks
- Low preportion of income is paid as dividend
Risk Factors
- Overvalued on cashflow basis
- Income is not covering expenditure and investment
- Earnings are negative 0
- No margin of safety at their current market price
- Disliked by Twitter users
- Poor earnings and cashflow growth
- Accounting anomalies: Growing revenues without a corresponding growth in cash flows. 0
Latest News
SQZ Biotechnologies to Present at Upcoming Investor Conferences
Business Wire | 22:30 Wed 7 Sept 2022
Read More →
Biopharmaceutical Stocks: The Bottoming Process Is Playing Out
Seeking Alpha | 20:30 Wed 8 Jun 2022
Read More →
SQZ Biotechnologies to Present at Jefferies Healthcare Conference
Business Wire | 22:45 Wed 1 Jun 2022
Read More →
SQZ Biotechnologies to Present at Upcoming Investor Conferences
Business Wire | 22:45 Wed 6 Apr 2022
Read More →
Market Peers
SQZ
Key Figures
PE Ratio (TTM)
N/A
Margin Of Safety (DCF)
-12228.84%
Revenue Growth (5 Year Average)
20.15%
Ratings Consensus
Buy
Share Buybacks
27.90%
Dividend Yeild (TTM)
N/A
Valuation
Value Score
1
Desired Margin Of Safety
0%
▼
Tip: Set your desired Margin Of Safety
Free Cash Flow Type
Annual Cashflow Growth
0%
Discount Rate
0%
Buy Target: N/A✘
Current Price: 0.6 USD
Negative Cashflows: Cashflow can become negative due to operating losses, investing activities or financing activites. Negative cashflow makes it dificult to use a discounted free cashflow model to assess intrinsic value.
How Does This Work?
Show Advanced Options
This calculator helps investors estimate the Intrinsic Value of a company based on the current value of future cash flows. To use the tool, simply input a desired Margin Of Safety, which is an additional discount applied to the present value of the expected future cash flows. The tool calculates the present value using a discount rate that reflects the risk and time value of money, and provides an estimated target price for the company based on the selected margin of safety. The calculator defaults to using 5 Year Free Cash Flow Growth % and a discount rate based on the US 10-year treasury bond coupon rate. Use our performance analyser to get a feel the impact this has on longterm investment returns and discover a margin of safety you are comfortable with. This can be a useful tool for investors looking to make informed decisions about whether to buy or sell shares of a particular company.
Price/Earnings
N/Ax
Free Cashflow Yeild
-516.25%
PE/Earnings Growth
N/A
Price/Book
0.24x
Growth
Growth Score
31
- ✔ 5 Year Average Revenue growth of 20.15% is higher than the market average (10.97%)
- ✔ Earnings growth has improved this year
- ✔ Free Cashflow growth has improved this year
- ✘ Revenue growth has slowed this year
- ✘ 5 Year Average Earnings growth of 0.38% is lower than the market average (14.48%)
- ✘ 5 Year Average Free Cashflow growth of -8.43% is lower than the market average (12.35%)
Revenue Growth
20.15%
Earnings Growth
0.38%
Cashflow Growth
-8.43%
Health
Health Score
45
Altman Z Score
N/A
Piostroski Score
1.00
Debt/Equity
0.56x
Current Assets/Liabilities
4.53x
Free Cashflow/Total Debt
N/Ax
Debt/Capital
0.46x
Management
Management Score
11
Average Buybacks/Dilution
27.90%
Recent Buybacks/Dilution
N/A
5 Year Price Volitility
36.26%
Return On Assets
-31.91%
Return On Capital Employed
-18.00%
Return On Equity
-58.22%
Return On Free Cashflow
162.82%
Return On Investments
N/A
Analysts
Analyst Opinion
69
- ✔ Ratings consensus is Buy
SEC Filings
Find yearly (10-K), quaterly (10-Q) and disclosure (8-K) report here, on the Securities and Exchange Commission's EDGAR database. If reading through reports isn't your cup of tea, don't worry. We've made it easy for you by summarizing all the important bits.
Other Information
Company Name
Currency
USD
Beta
Vol Avg
Ceo
Dr. Armon R. Sharei
Cik
0001604477
Cusip
78472W104
Exchange
New York Stock Exchange
Full Time Employees
Industry
Biotechnology
Sector
Healthcare
Ipo Date
Address
200 Arsenal Yards Boulevard
City
Watertown
State
MA
Country
Zip
02472
Phone
617 758 8672
All financial data provided by FMP
Social Sentiment
Social Sentiment Score
27
Twitter Sentiment
N/A
Stocktwits Sentiment
53.00